Our Team Australia
Our Board
Our Board Members include Founding Members Giovi and Charles Moschoudis, parents to Angelina who has CASK Gene Disorder.
Each of our board members volunteer and dedicate their time to this extraordinary cause.
Our Board Members include Founding Members Giovi and Charles Moschoudis, parents to Angelina who has CASK Gene Disorder.
Each of our board members volunteer and dedicate their time to this extraordinary cause.
Giovi is the Founder of the Angelina Cask Neurological Foundation (ACNRF), established in both Sydney, Australia, and California, USA.
Giovi is married to Charles Moschoudis, and they have two children Aydan who is diagnosed with Autism and their youngest daughter Angelina, is diagnosed with CASK Gene Disorder.
An experienced lawyer and leader, Giovi has worked in both the private and public sectors before founding ACNRF. She is a genuine, focused, and enthusiastic leader, committed to achieving the foundation’s goals of improving the quality of life for those diagnosed with CASK.
A passionate advocate in the rare diseases space, she seeks to garner support from both private and public sectors to facilitate collaboration within the scientific and medical communities, thereby advancing innovation in the diagnosis and treatment of CASK Gene Disorders and related conditions.
Charles is Angelina’s father.
He has over two decades of experience in the provision of leadership, guidance, and advice at senior levels in both the public and private sector.
Dr Moschoudis is an Adjunct Professor at Torrens University Australia (AGSL).
Karina has completed a Bachelor of Education at the Australian Catholic University and Masters of Education Leadership at Macquarie University.
Karina has highly developed interpersonal skills and works closely with committed and skilled professionals.
During Karina’s teaching experience, she has been heavily involved in data analysis and leadership responsibilities.
Karina is currently the co-ordinator and leads a team who provide learning support for children who have special needs.
Anthony Moschoudis is a Senior Executive in the financial sector.
He has considerable experience in the private sector in the context of corporate leadership, having taken on various board appointments.
He has a wealth of strategic and operational experience relevant to corporate governance and management.
Brooke is a proud mum to radiant Em, who lives with CASK Gene Disorder. With a background in corporate roles across the insurance and financial services sectors, she brings strategic insight and professional experience to her purpose-driven work at CureCASK.
As Relationships Leader for Strategic Philanthropy, Brooke is dedicated to fostering meaningful connections, supporting fundraising initiatives, and strengthening the CASK community to drive research and awareness forward.
My name is Keeda Zilm, and I’m excited to be part of the ACNRF team. I’m based in Adelaide and work as a winemaker in the beautiful Barossa Valley.
I’m really enjoying my volunteer role with the Foundation—it’s been such a rewarding experience. I’m learning so much and gaining a deeper insight into the incredible families we support.
Hi everyone! My name is Valerie, and I’m thrilled to be joining ACNRF as a volunteer. I’m currently studying neuroscience at the University of Melbourne and am excited to contribute, learn, and grow during my time here. I look forward to being part of the team and making a meaningful impact!
Lavvina is a clinical genetics fellow from NSW, Australia with a background in general paediatrics. She has practiced in multiple tertiary paediatric hospitals in Australia, both in general paediatrics and clinical genetics. She currently provides specialist advice for the NGO, Taking Paediatrics Abroad and is a member of GeneEQUAL, an inclusive research group aiming to improve accessibility of genetic testing and care for people with intellectual disability by co-design.
Lavvina’s clinical interests are in the genetics of autism, intellectual disability and immunogenomics. She is particularly passionate about including the patient groups she works with in research and healthcare decisions.
Lavvina is affiliated with The Children’s Hospital Westmead and the University of New South Wales where she is undertaking a Masters by Research, co-producing a model of genetic healthcare that aligns with the preferences of Autistic people.
I, the undersigned, give my consent to the Angelina CASK Neurological Research Foundation Ltd and Angelina CASK Neurological Research Foundation Inc (ACNRF) to use photographs, videos, or other media featuring me, my child, or an individual under my legal guardianship (“Media Materials”).
This consent permits ACNRF to use these Media Materials for purposes such as:
I understand that these materials may be distributed publicly and may appear in print, digital, and other media formats worldwide and in perpetuity.
Terms and Conditions:
1. Usage Rights: I grant ACNRF the right to edit, adapt, or modify the Media Materials as needed for the purposes outlined above.
2. No Compensation: I acknowledge that no monetary or other compensation will be provided for the use of the Media Materials.
3. Release of Claims: I waive any rights to inspect or approve the final product and release ACNRF from any claims, liabilities, or damages related to the use of the Media Materials, including but not limited to claims of defamation, privacy, or copyright infringement.
4. Ownership Confirmation: I confirm that I have the authority to grant these rights for the provided Media Materials and that they do not infringe on the rights of any third party.
This authorisation is voluntary and may be revoked by written notice to ACNRF at any time, though I understand that materials already published may not be withdrawn.
“In some ways, that CASK-linked pathology is degenerative in nature provides a positive outlook. Because microcephaly in CASK-linked pathology progresses postnatally, there may be a temporal window when therapeutic intervention might prevent or slow further brain cell loss. Regression, even in adolescence, has also been observed in some cases of MICPCH [119], again offering the tantalizing possibility that a therapeutic approach might prevent such decline under conditions when degeneration is known to progress. The potential benefits of intervention might extend even further given that non-cell-autonomous toxicity could also affect functioning of the remaining neurons; reduction of such toxicity, especially when coupled with high-intensity rehabilitative measures [120], might offer real hope for a positive impact on functional outcomes.”
